The 2025 MISTRs Are Here — and They're Hotter Than Free Online PrEP
From viral creators to queer heartthrobs, this year's MISTRs are serving face, body, and free sexual healthcare for all
The 2020 MISTRs
MISTR: Free online PrEP, DoxyPEP & STI Testing
Miami, FL, June 10, 2025 (GLOBE NEWSWIRE) -- Things just got hotter. MISTR, the nation's #1 LGBTQ+ telehealth platform for sexual health, is proud to unveil the new class of MISTRs for 2025 — twelve bold, beautiful, and totally unfiltered ambassadors who are bringing free sexual healthcare to your feed and your bedroom.
Serving more than 500,000 patients served nationwide, MISTR makes it easy to stay protected. Patients can sign up online for PrEP — a once-a-day pill that reduces the risk of HIV by 99% — and DoxyPEP, an antibiotic taken after sex that helps prevent common STIs like syphilis, chlamydia, and gonorrhea. When bundled together, they offer next-level protection — and MISTR makes it 100% free, fast, and delivered discreetly to your door.
'Being a MISTR means showing up — shirtless, fearless, and fully protected,' said Tristan Schukraft, Founder and CEO of MISTR. 'These guys are fun, fearless, and fully committed to making HIV prevention sexy and stigma-free.'
This year's lineup includes digital disruptors, fitness kings, and unapologetically queer content creators — including model and LGBTQ+ heartthrob Bruno Alcantara and the sizzling creator and advocate Kyle Krieger — all teaming up with MISTR to spread the word (and maybe more). Each MISTR will appear in exclusive video content, social collabs, and events promoting MISTR's 100% free online access to PrEP, DoxyPEP, STI testing, and long-term HIV care – all available online at mistr.com with or without insurance.
The full 2025 MISTR roster:
Bruno Alcantara
Harold Cabrera Ruiz
Chase Carlson
Christian Dante White
Dany Juvier
Kyle Krieger
Jordan Lipes
David Oberto
Robert Pérez
Ty Talley
Doryin Thames
Dru Vu
Together, they'll be showing the world that taking care of your sexual health doesn't have to be boring, awkward, or expensive. It can be hot, fast, free, and delivered to your door.
Follow the campaign at @heymistr, and visit mistr.com to get on PrEP or DoxyPEP with zero cost, zero judgment, and zero excuses.
# # #
ABOUT MISTRMISTR is a telemedicine platform offering free online access to pre-exposure prophylaxis (PrEP) DoxyPEP, STI Testing and long-term HIV care in all 50 states, D.C. and Puerto Rico. Gay owned and operated, MISTR has brought together a network of the best doctors, pharmacists, and problem solvers to make PrEP, DoxyPEP and long-term HIV care available to all who need it. No doctor's office, no paperwork and free delivery. Learn more at www.mistr.com.
Attachments
The 2020 MISTRs
MISTR: Free online PrEP, DoxyPEP & STI Testing
CONTACT: Brian Rosman MISTR 323.443.7780 mistr@dogandaduck.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Global Fatty Liver Day 2025: Elevating Liver Health in the Metabolic Health Conversation
Global Liver Institute Calls for Urgent Action as Fatty Liver Disease Prevalence Surges Worldwide Today is Global Fatty Liver Day Washington, D.C., June 11, 2025 (GLOBE NEWSWIRE) -- On the second Thursday in June, Global Fatty Liver Day (formerly International NASH Day) spotlights one of the most widespread yet under-addressed health threats of our time: fatty liver disease, increasingly referred to as steatotic liver disease (SLD) in clinical settings. Hosted annually by Global Liver Institute (GLI), this public awareness campaign raises awareness of this silent epidemic and its deep roots in global metabolic health liver disease, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated alcohol-related liver disease (MetALD), impacts millions globally—yet most remain undiagnosed and untreated. Once considered rare, fatty liver disease has surged in parallel with rising rates of obesity, diabetes, and other metabolic estimated 30.2% of the global population now lives with MASLD, with rates soaring to 57.5% among adults with obesity. In the United States alone, more than 122 million adults are projected to be affected by R. Holden, President and CEO of Global Liver Institute, states, 'The liver is no longer the silent organ. Fatty liver disease is now one of the clearest and most urgent signs of global metabolic dysfunction. On Global Fatty Liver Day, we call on healthcare leaders, policymakers, and the public to recognize the liver's central role in preventing not just liver disease—but cardiovascular disease, diabetes, and other non-communicable diseases (NCDs). Liver health must rise to the top of public health agendas globally.'Fatty liver disease develops when excess fat accumulates in the liver, often without symptoms in its early stages. Left unaddressed, it can progress to inflammation, fibrosis, cirrhosis, liver cancer, and even death. In fact, MASH is now one of the leading causes of liver transplantation in the fatty liver disease doesn't occur in isolation: Up to 75% of people with type 2 diabetes also have MASLD Over 70% of people with MASLD also live with obesity Between 20% and 80% of individuals with high cholesterol or triglycerides are also affected by fatty liver disease 'Fatty liver disease is not just about the liver—it's about the entire metabolic ecosystem,' said Sharon Jaycox, PhD, Fatty Liver Disease Program Director at GLI. 'If we fail to address it, we miss a major opportunity to detect and treat metabolic dysfunction early. We must educate patients and providers alike, embed liver screening in diabetes and obesity care, and drive equitable access to diagnostics and care.' GLI urges coordinated action across health systems, communities, and governments to: Incorporate liver screening into routine care for those with obesity, diabetes, and other metabolic risks Educate the public and clinicians about MASLD, MASH, and MetALD as part of integrated metabolic care Expand access to affordable, noninvasive diagnostic tools Support policies and funding that reflect the scale and urgency of the fatty liver disease crisis As GLI continues to lead this global awareness effort, we invite stakeholders to join us in bringing liver health into every metabolic health to learn more, access resources, and take action on Global Fatty Liver Day. Attachment Today is Global Fatty Liver Day CONTACT: Christine Maalouf Global Liver Institute cmaalouf@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adults with steroid refractory acute graft versus host disease (SR-aGvHD). In the first week of June, Mesoblast held a Type B meeting with FDA under its Regenerative Medicines Advanced Therapy (RMAT) designation for REVASCOR to discuss components of a potential filing for a Biologics License Application (BLA). There was general alignment on items regarding chemistry, manufacturing & controls (CMC), potency assays for commercial product release, and proposed design and primary endpoint for the confirmatory trial post-approval. The Company will await the final minutes from FDA in order to provide detailed feedback and timelines for potential filing. In early July, Mesoblast has an upcoming meeting with FDA to discuss a pivotal trial of Ryoncil® in adults with SR-aGvHD. This trial will be conducted with the NIH-funded Bone Marrow Transplant Clinical Trials Network (BMT-CTN), the objective being to extend the product's label from children to adults with SR-aGvHD. Ryoncil® is the first and only mesenchymal stromal cell product approved by the FDA for any indication. Ryoncil® became commercially available for purchase in the United States on March 28, 2025, within one quarter of receiving FDA approval to treat children with SR-aGvHD. More than 20 transplant centers will have been onboarded by the end of the quarter, exceeding the company's expectations at product launch. Mesoblast has continued to expand coverage for Ryoncil® to over 220 million US lives insured by commercial and government payers. To date, 37 of the 51 States provide fee-for-service Medicaid coverage for Ryoncil® through Orphan Drug Lists or medical exception / prior authorization (PA) process. The remainder will come online July 1, 2025, with mandatory coverage for all 24 million lives. 'We are very pleased with the momentum of interactions with FDA on both our cardiac and GvHD programs,' said Mesoblast Chief Executive Dr. Silviu Itescu. 'We are also encouraged by the strength of the of the Ryoncil® commercial launch, the rate of hospital onboarding, physician adoption, and payor coverage exceeding our expectations in the ten weeks since commercial launch. We will be providing an update on sales of Ryoncil® in our quarterly activities report at the end of next month.' About Mesoblast Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company's proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process. Mesoblast's RYONCIL® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. RYONCIL is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China. About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications are expected to provide commercial protection extending through to at least 2041 in major markets. About Mesoblast manufacturing: The Company's proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see LinkedIn: Mesoblast Limited and X: @Mesoblast Forward-Looking StatementsThis press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast's preclinical and clinical studies, and Mesoblast's research and development programs; Mesoblast's ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast's ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast's RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast's product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast's ability to enter into and maintain established strategic collaborations; Mesoblast's ability to establish and maintain intellectual property on its product candidates and Mesoblast's ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast's expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast's financial performance; developments relating to Mesoblast's competitors and industry; and the pricing and reimbursement of Mesoblast's product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise. Release authorized by the Chief Executive. For more information, please contact:Paul Hughes T: +61 3 9639 6036 Allison Worldwide Emma Neal T: +1 603 545 4843 E: BlueDot Media Steve Dabkowski T: +61 419 880 486 E: steve@
Yahoo
2 hours ago
- Yahoo
Matthew 25 unveils mobile STD testing unit
HENDERSON, Ky (WEHT) – The non-profit organization Matthew 25 held a ribbon cutting to celebrate its campaign to help prevent, educate and treat people in the Tri-State with Sexual Transmitted Diseases. Last August, The Centers for Disease Control and Prevention granted $3,000,000 in funding to the organization. Matthew 25 used a large portion of that grant in partnership with Mission Mobile Medical to customize the treatment center. As for why this was needed, Chief Executive Officer, Courtney Woolfork, said, 'We have clinics in Owensboro, Henderson, and Bowling Green. But everything in between is really hard for people to get access to, because there isn't public transportation always.' The non-profit covers 25 counties in Kentucky and 12 in Indiana and officials say that they have seen STD trends increasing in those regions. Woolfork says that trends like these are why it's so beneficial to have a mobile treatment unit that can serve vulnerable areas. The mobile unit will also have PREP pills available to those who have had a Sexually Transmitted Illnesses. Matthew 25 urges those who have come in contact with an STD or STI to get this pill to lessen their chances of contracting HIV in the future. Over the next couple months, Woolfork and her team plan on traveling to 25 counties in the Tri-State. March 27 will kick off the road trip, as they will be in Owensboro, Kentucky for National HIV Testing Day. Although they are fighting an uphill battle the mission statement is clear, 'Meeting people where they are and however they are.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
